We research genetic questions to help you make important decisions about your health.

MiraKind conducts cutting-edge research on a new class of genetic markers that provides powerful information about personalized disease risk, treatment, and management.

What We Do

MiraKind conducts patient-centric research to better understand novel inherited gene mutations, such as the KRAS-variant, to help:

discover-2
Discover Answers

Discover clues in our DNA to identify individuals who are at higher risk of certain diseases, such as cancer.

prevent
Mitigate Risk

Apply answers to mitigate an individual’s disease risk through personalized prevention based on one's unique genetics.

treat
Treat Disease

Recommend the most effective pathways for treatment, based on an individual’s unique response to therapy.

What we know about treatment for:

Cancer Diagnosis

Learn About Treatment

What We Believe

Knowledge Is Power

We have an endless list of questions, relentless determination to find the answers, and conviction in sharing our research findings.

We CAN Do Better

We CAN Do Better in the fight against cancer, and other devastating diseases, but it takes all of us to join the battle.

Together We Are Stronger

Which is why we provide a place where our members can share stories, learn from each other, and connect in a meaningful way. Visit the MiraKind community.

The KRAS-Variant

The KRAS-variant is the most widely studied genetic marker in a new class of genetic markers known as MicroRNA Disrupting Mutations.

Discovered in 2007 by Joanne Weidhaas, MD, PhD, and Frank Slack, PhD, the KRAS-variant is an inherited gene mutation associated with increased cancer risk.  Dozens of studies over the last decade have revealed that individuals with the KRAS-variant have access to powerful information that can explain a family history of cancer and help guide healthcare decisions such as hormone replacement therapy.

Learn more about the KRAS-Variant

“It’s wonderful to feel that my participation in a study may have such meaning for others. I am so grateful my daughter, my daughter-in-law, and all young women will benefit from your efforts. For the first time since my diagnosis, I felt more powerful than my cancer.”

Read other’s stories

true-believer-cover

FROM THE DECEMBER 2014 ISSUE

The Little-Known Genetic Mutation Behind Many Aggressive Cancers

Despite the dangers of the KRAS-variant mutation, few doctors have heard of it. But one researcher is trying to change that.

Read more

DONATE

SUPPORT OUR RESEARCH

PARTICIPATE

HELP ADVANCE OUR RESEARCH